share_log

Allarity Therapeutics | 8-K: Current report

Allarity Therapeutics | 8-K: Current report

Allarity Therapeutics | 8-K：重大事件
美股SEC公告 ·  05/21 08:20

Moomoo AI 已提取核心信息

Allarity Therapeutics, Inc. (Allarity), a clinical-stage biopharmaceutical company, has announced on May 20, 2024, that it has regained compliance with the Nasdaq's minimum stockholders' equity requirement. This follows the company's strategic efforts to improve its financial position, which included raising new equity and reducing liabilities. The compliance confirmation from Nasdaq comes after Allarity's presentation of a strategic plan during a panel hearing in February 2024. The company has also amended its At-The-Market Issuance Sales Agreement with Ascendiant Capital Markets, LLC, increasing the amount of Placement Shares that may be sold to $30 million as of May 17, 2024. Allarity is focused on advancing its lead asset, stenoparib, a therapy for advanced ovarian cancer, and will continue to use its Drug Response Predictor (DRP®) companion diagnostic to select patients for treatment in clinical trials. The company will be monitored by a Nasdaq panel for one year to ensure continued compliance.
Allarity Therapeutics, Inc. (Allarity), a clinical-stage biopharmaceutical company, has announced on May 20, 2024, that it has regained compliance with the Nasdaq's minimum stockholders' equity requirement. This follows the company's strategic efforts to improve its financial position, which included raising new equity and reducing liabilities. The compliance confirmation from Nasdaq comes after Allarity's presentation of a strategic plan during a panel hearing in February 2024. The company has also amended its At-The-Market Issuance Sales Agreement with Ascendiant Capital Markets, LLC, increasing the amount of Placement Shares that may be sold to $30 million as of May 17, 2024. Allarity is focused on advancing its lead asset, stenoparib, a therapy for advanced ovarian cancer, and will continue to use its Drug Response Predictor (DRP®) companion diagnostic to select patients for treatment in clinical trials. The company will be monitored by a Nasdaq panel for one year to ensure continued compliance.
处于临床阶段的生物制药公司Allarity Therapeutics, Inc.（Alarity）于2024年5月20日宣布，它已恢复遵守纳斯达克的最低股东权益要求。在此之前，该公司采取了改善财务状况的战略举措，包括筹集新股权和减少负债。纳斯达克的合规确认是在Alarity在2024年2月的小组听证会上提出战略计划之后作出的。该公司还修订了与Ascendiant Capital Markets, LLC的市场发行销售协议，将截至2024年5月17日可能出售的配售股份数量增加至3000万美元。Alarity专注于推进其主要资产stenoparib（一种晚期卵巢癌的治疗方法），并将继续使用其药物反应预测器（DRP®）伴随诊断来选择患者进行临床试验的治疗。该公司将接受纳斯达克小组为期一年的监督，以确保持续合规。
处于临床阶段的生物制药公司Allarity Therapeutics, Inc.（Alarity）于2024年5月20日宣布，它已恢复遵守纳斯达克的最低股东权益要求。在此之前，该公司采取了改善财务状况的战略举措，包括筹集新股权和减少负债。纳斯达克的合规确认是在Alarity在2024年2月的小组听证会上提出战略计划之后作出的。该公司还修订了与Ascendiant Capital Markets, LLC的市场发行销售协议，将截至2024年5月17日可能出售的配售股份数量增加至3000万美元。Alarity专注于推进其主要资产stenoparib（一种晚期卵巢癌的治疗方法），并将继续使用其药物反应预测器（DRP®）伴随诊断来选择患者进行临床试验的治疗。该公司将接受纳斯达克小组为期一年的监督，以确保持续合规。
有用
没用

该公告为独立文件：

独立文件1  查看翻译

独立文件2  查看翻译

独立文件3  查看翻译

声明：本内容仅用作提供资讯及教育之目的，不构成对任何特定投资或投资策略的推荐或认可。 更多信息
    热议
    美股
    股票代码最新价涨跌幅

    暂无数据

    资讯热榜
    更新时间